Compare Stocks: ACHV, TRVI, BHC, and PBH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.91 +3.6%	$5.96	$2.37 ▼ $7.11	$708.25M	2.24	1.29 million shs	792,630 shs
BHC Bausch Health Cos	$6.18 -2.8%	$5.11	$4.33 ▼ $8.69	$2.31B	0.38	2.54 million shs	533,575 shs
PBH Prestige Consumer Healthcare	$53.72 +1.4%	$48.96	$42.62 ▼ $71.07	$2.55B	0.34	563,981 shs	131,858 shs
TRVI Trevi Therapeutics	$17.57 -1.3%	$17.05	$6.93 ▼ $20.22	$2.50B	1.03	1.73 million shs	493,338 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+0.30%	+5.54%	+9.17%	+11.35%	+166.80%
BHC Bausch Health Cos	+1.67%	-9.51%	+32.77%	+17.30%	+9.88%
PBH Prestige Consumer Healthcare	-3.89%	+1.75%	+7.91%	+4.47%	-19.54%
TRVI Trevi Therapeutics	-3.84%	-0.56%	-0.22%	+20.60%	+139.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.91 +3.6%	$5.96	$2.37 ▼ $7.11	$708.25M	2.24	1.29 million shs	792,630 shs
BHC Bausch Health Cos	$6.18 -2.8%	$5.11	$4.33 ▼ $8.69	$2.31B	0.38	2.54 million shs	533,575 shs
PBH Prestige Consumer Healthcare	$53.72 +1.4%	$48.96	$42.62 ▼ $71.07	$2.55B	0.34	563,981 shs	131,858 shs
TRVI Trevi Therapeutics	$17.57 -1.3%	$17.05	$6.93 ▼ $20.22	$2.50B	1.03	1.73 million shs	493,338 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+0.30%	+5.54%	+9.17%	+11.35%	+166.80%
BHC Bausch Health Cos	+1.67%	-9.51%	+32.77%	+17.30%	+9.88%
PBH Prestige Consumer Healthcare	-3.89%	+1.75%	+7.91%	+4.47%	-19.54%
TRVI Trevi Therapeutics	-3.84%	-0.56%	-0.22%	+20.60%	+139.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$16.00	131.45% Upside
BHC Bausch Health Cos	1.71	Reduce	$8.00	29.55% Upside
PBH Prestige Consumer Healthcare	2.00	Hold	$70.75	31.70% Upside
TRVI Trevi Therapeutics	3.00	Buy	$26.75	52.24% Upside

Current Analyst Ratings Breakdown

Latest ACHV, TRVI, BHC, and PBH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00
8/7/2026	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$40.00
8/7/2026	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $30.00
7/31/2026	BHC Bausch Health Cos	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/24/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/22/2026	BHC Bausch Health Cos	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$36.00
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	TRVI Trevi Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $31.00
7/20/2026	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $24.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
BHC Bausch Health Cos	$10.27B	0.22	$7.18 per share	0.86	$1.02 per share	6.05
PBH Prestige Consumer Healthcare	$1.09B	2.34	$5.10 per share	10.53	$39.89 per share	1.35
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.12	N/A	N/A	N/A	N/A	-193.49%	-111.88%	N/A
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.57	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	15.05	11.45	1.70	15.57%	11.39%	5.66%	N/A
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	N/A

Latest ACHV, TRVI, BHC, and PBH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.28	-$0.1151	-$0.80	N/A	N/A
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion
5/13/2026	Q4 2026	PBH Prestige Consumer Healthcare	$1.39	$1.23	-$0.16	$1.13	$293.64 million	$281.62 million
5/12/2026	Q1 2026	ACHV Achieve Life Sciences	-$0.30	-$0.19	+$0.11	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	2.62	2.62
BHC Bausch Health Cos	54.68	1.44	1.08
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
TRVI Trevi Therapeutics	N/A	37.28	37.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
BHC Bausch Health Cos	78.65%
PBH Prestige Consumer Healthcare	99.95%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
BHC Bausch Health Cos	20.67%
PBH Prestige Consumer Healthcare	1.50%
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.66 million	100.81 million	Optionable
BHC Bausch Health Cos	20,300	373.99 million	296.69 million	Optionable
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable
TRVI Trevi Therapeutics	20	142.48 million	120.55 million	Optionable

ACHV, TRVI, BHC, and PBH Headlines

Recent News About These Companies

1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A.

August 10 at 3:11 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $30.00

August 10 at 2:12 AM | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates

August 7, 2026 | marketbeat.com

Trevi Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

August 7, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | globenewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages

August 5, 2026 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

July 31, 2026 | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Trevi Therapeutics (TRVI) to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2026 | globenewswire.com

Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI

July 25, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

July 25, 2026 | marketbeat.com

Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets

July 22, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why

July 20, 2026 | marketbeat.com

B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

July 20, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, TRVI, BHC, and PBH Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$6.91 +0.24 (+3.64%)

As of 12:16 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Bausch Health Cos NYSE:BHC

$6.18 -0.18 (-2.76%)

As of 12:15 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Prestige Consumer Healthcare NYSE:PBH

$53.72 +0.72 (+1.36%)

As of 12:16 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Trevi Therapeutics NASDAQ:TRVI

$17.57 -0.23 (-1.29%)

As of 12:15 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, TRVI, BHC, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, TRVI, BHC, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, TRVI, BHC, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, TRVI, BHC, and PBH Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Bausch Health Cos NYSE:BHC

Prestige Consumer Healthcare NYSE:PBH

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHV, TRVI, BHC, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHV, TRVI, BHC, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHV, TRVI, BHC, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, TRVI, BHC, and PBH Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Bausch Health Cos NYSE:BHC

Prestige Consumer Healthcare NYSE:PBH

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools